Remicade Gets First-Line Rheumatoid Arthritis Claim On Data In Early Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's infliximab is approved for first-line RA treatment in combination with methotrexate. Approval is based on 54-week ASPIRE trial showing superiority in early RA; study also shows preventative benefit in patients without initial joint damage.
You may also be interested in...
Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says
Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”
Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says
Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”
Amgen Polishes Enbrel Label
The TNF-inhibitor adds first-in-class claim for “major clinical response” in rheumatoid arthritis and gets approval for new once-weekly prefilled syringe. Five-year radiographic data also added to the label.